Gastrointestinal Cancer News

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed the importance of biomarker testing and the challenges involved.

Radiotherapy after induction chemotherapy improved R0 circumferential resection margin-negative resection and pathologic complete response rates among patients with pancreatic cancer without a significant increase in R0 resection rate.

In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.

In a meta-analysis of triluridine/tipiracil (TAS-102) plus bevacizumab triluridine/tipiracil alone, there was a benefit to adding bevacizumab for patients with lateline colorectal cancer that is metastatic.

In this video, Timothy Brown, MD, discussed the results of his study on treatment outcomes of patients with platinum-sensitive BRCA or PALB2-mutated pancreatic cancer who have been treated with and progressed on rucaparib.

In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.

In this video, Robert Vonderheide, MD, DPhil, discussed the results of the phase 2 randomized study of chemoimmunotherapy for patients with metastatic pancreatic cancer.

As they work to anticipate and meet the needs of their loved ones, caregivers of individuals with cancer often struggle with their own complex emotional, physical and social concerns.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.